High fever following postpartum administration of sublingual misoprostol
- PMID: 20406228
- PMCID: PMC2878599
- DOI: 10.1111/j.1471-0528.2010.02564.x
High fever following postpartum administration of sublingual misoprostol
Abstract
Objective: To explore what triggers an elevated body temperature of > or =40.0 degrees C in some women given misoprostol, a prostaglandin E1 analogue, for postpartum haemorrhage (PPH).
Design: Post hoc analysis.
Setting: One tertiary-level hospital in Quito, Ecuador.
Population: A cohort of 58 women with a fever of above 40 degrees C following treatment with sublingual misoprostol (800 micrograms) for PPH.
Methods: Side effects were documented for 163 Ecuadorian women given sublingual misoprostol to treat their PPH. Women's body temperatures were measured, and if they had a fever of > or =40.0 degrees C, measurements were taken hourly until the fever subsided. Temperature trends were analysed, and the possible physiological mechanisms by which postpartum misoprostol produces a high fever were explored.
Main outcome measures: The onset, duration, peak temperatures, and treatments administered for cases with a high fever.
Results: Fifty-eight of 163 women (35.6%) treated with misoprostol experienced a fever of > or =40.0 degrees C. High fevers followed a predictable pattern, often preceded by moderate/severe shivering within 20 minutes of treatment. Body temperatures peaked 1-2 hours post-treatment, and gradually declined over 3 hours. Fevers were transient and did not lead to any hospitalisation. Baseline characteristics were comparable among women who did and did not develop a high fever, except for known previous PPH and time to placental expulsion.
Conclusions: An unexpectedly high rate of elevated body temperature of > or =40.0 degrees C was documented in Ecuador following sublingually administered misoprostol. It is unclear why temperatures > or =40.0 degrees C occurred with a greater frequency in Ecuador than in other study populations using similar treatment regimens for PPH. Pharmacogenetic studies may shed further light on variations in individuals' responses to misoprostol.
Figures
Similar articles
-
High fever after sublingual administration of misoprostol for treatment of post-partum haemorrhage: a hospital-based, prospective observational study in Argentina.Trop Med Int Health. 2020 Jun;25(6):714-722. doi: 10.1111/tmi.13389. Epub 2020 Apr 16. Trop Med Int Health. 2020. PMID: 32155681 Free PMC article.
-
Dose and side effects of sublingual misoprostol for treatment of postpartum hemorrhage: what difference do they make?BMC Pregnancy Childbirth. 2012 Jul 7;12:65. doi: 10.1186/1471-2393-12-65. BMC Pregnancy Childbirth. 2012. PMID: 22769055 Free PMC article.
-
Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital-based randomized-controlled trial in Karachi, Pakistan.BMC Pregnancy Childbirth. 2008 Aug 21;8:40. doi: 10.1186/1471-2393-8-40. BMC Pregnancy Childbirth. 2008. PMID: 18718007 Free PMC article. Clinical Trial.
-
Prevention of postpartum hemorrhage with misoprostol.Int J Gynaecol Obstet. 2007 Dec;99 Suppl 2:S198-201. doi: 10.1016/j.ijgo.2007.09.012. Epub 2007 Oct 24. Int J Gynaecol Obstet. 2007. PMID: 17961574 Review.
-
Misoprostol for the prevention and treatment of postpartum hemorrhage.Expert Opin Investig Drugs. 2012 Feb;21(2):235-50. doi: 10.1517/13543784.2012.647405. Epub 2012 Jan 11. Expert Opin Investig Drugs. 2012. PMID: 22233426 Review.
Cited by
-
High fever after sublingual administration of misoprostol for treatment of post-partum haemorrhage: a hospital-based, prospective observational study in Argentina.Trop Med Int Health. 2020 Jun;25(6):714-722. doi: 10.1111/tmi.13389. Epub 2020 Apr 16. Trop Med Int Health. 2020. PMID: 32155681 Free PMC article.
-
Misoprostol Induced Convulsion-A Rare Side Effect of Misoprostol.J Clin Diagn Res. 2017 Feb;11(2):QD01-QD02. doi: 10.7860/JCDR/2017/23396.9189. Epub 2017 Feb 1. J Clin Diagn Res. 2017. PMID: 28384938 Free PMC article.
-
Sublingual misoprostol and hyperpyrexia: case report with temperature curve.BMC Res Notes. 2017 Jul 26;10(1):329. doi: 10.1186/s13104-017-2661-2. BMC Res Notes. 2017. PMID: 28747212 Free PMC article.
-
Sublingual Misoprostol-Induced Rhabdomyolysis and Convulsions in Postpartum Hemorrhage: A Case Report and Literature Review.Cureus. 2024 May 8;16(5):e59874. doi: 10.7759/cureus.59874. eCollection 2024 May. Cureus. 2024. PMID: 38854268 Free PMC article.
-
Effectiveness and safety of misoprostol distributed to antenatal women to prevent postpartum haemorrhage after child-births: a stepped-wedge cluster-randomized trial.BMC Pregnancy Childbirth. 2015 Nov 26;15:315. doi: 10.1186/s12884-015-0750-6. BMC Pregnancy Childbirth. 2015. PMID: 26610333 Free PMC article. Clinical Trial.
References
-
- Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2007 DOI: 10.1002/14651858.CD000494.pub3. - DOI - PubMed
-
- Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2007 DOI: 10.1002/14651858.CD003249.pub2. - DOI - PubMed
-
- Hofmeyr GJ, Gülmezoglu AM. Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008;22:1025–41. - PubMed
-
- WHO Department of Reproductive Health and Research . WHO statement regarding the use of misoprostol for postpartum haemorrhage prevention and treatment. WHO; 2009.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical